CareTrust REIT, Inc
CTRE
$37.03
-0.03%
CareTrust REIT, Inc. is a self-administered, publicly traded real estate investment trust that owns, acquires, finances, develops, and leases skilled nursing, seniors housing, and other healthcare-related properties. The company operates as a specialized healthcare REIT with a pure-play focus on triple-net lease arrangements, where tenants are responsible for property-level costs, providing a predictable income stream. The current investor narrative is driven by the company's strategic growth through acquisitions and development, coupled with the defensive nature of its healthcare real estate portfolio amid economic uncertainty, though recent stock volatility reflects market sensitivity to interest rate expectations and broader REIT sector performance.…
CTRE
CareTrust REIT, Inc
$37.03
Investment Opinion: Should I buy CTRE Today?
Rating & Thesis: CTRE is rated a HOLD. The core thesis is that the company's exceptional fundamental growth and profitability are compelling, but these strengths are fully priced in at current levels, and the stock faces significant near-term headwinds from sector sentiment and technical breakdown. The limited analyst consensus shows a positive bias (Overweight/Outperform), but provides no clear average price target for upside calculation.
Supporting Evidence: The hold rating is supported by four key data points. First, valuation is elevated with a trailing P/E of 22.97x, demanding sustained high growth. Second, while revenue growth is explosive at 117% YoY, this is acquisition-fueled and may not be repeatable. Third, profitability is stellar with a 67.26% net margin, providing a strong earnings base. Fourth, the technical picture has deteriorated sharply, with the stock down -13.17% in one month and breaking below its recent uptrend, suggesting momentum has shifted negatively in the short term.
Risks & Conditions: The two biggest risks to the thesis are 1) a further rise in interest rates compressing REIT multiples, and 2) a deceleration in acquisition-led growth. This HOLD would upgrade to a BUY if the stock's valuation corrects further towards its 52-week low (offering a higher margin of safety) or if the technical picture stabilizes above key support with a P/E compression below 20x. It would downgrade to a SELL if revenue growth decelerates sharply (e.g., below 20% YoY) or if the stock breaks decisively below its 52-week low of $27.81. Relative to its own history and the current macro environment for REITs, the stock appears fairly valued to slightly overvalued.
Sign up to view all
CTRE 12-Month Price Forecast
The outlook for CTRE is a tug-of-war between stellar company-specific execution and challenging macro/sector conditions. The base case of range-bound trading is most probable (55%), as the stock digests its recent gains and contends with interest rate uncertainty. The bullish scenario requires a favorable shift in monetary policy, while the bearish scenario hinges on a growth slowdown amid sustained high rates. The stance is neutral due to the offsetting forces; it would turn bullish on a sustained technical recovery above $41 coupled with evidence of organic growth, or bearish on a breakdown below $36 support and a deceleration in revenue growth below 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareTrust REIT, Inc's 12-month outlook, with a consensus price target around $48.14 and implied upside of +30.0% versus the current price.
Average Target
$48.14
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$30 - $48
Analyst target range
Analyst coverage appears limited, with data indicating only one firm providing estimates, which is insufficient to derive a meaningful consensus. The single analyst estimate projects an average EPS of $1.69 for the coming period, with a range from $1.63 to $1.76. The lack of a broad consensus target price and recommendation distribution suggests this is a smaller-cap REIT with limited institutional research coverage. This typically leads to higher volatility and less efficient price discovery, as the stock may be more susceptible to macro moves and specific company news rather than analyst herd behavior. The recent institutional ratings from firms like Wells Fargo (Overweight), RBC Capital (Outperform), and UBS (Buy) indicate a generally positive bias among the few covering analysts, with the most recent action in March 2026 being a reiteration. The absence of downgrades in the provided data points to maintained, if cautious, optimism among its follower base.
Bulls vs Bears: CTRE Investment Factors
The bull case is anchored in CTRE's exceptional fundamental performance: explosive revenue growth, industry-leading profitability, and a fortress balance sheet. The bear case highlights significant near-term technical deterioration and a valuation that appears to be pricing in perfection, especially given the stock's recent sharp underperformance. Currently, the fundamental evidence (bull) is stronger than the technical evidence (bear), but the two narratives are in direct conflict. The single most important tension in the investment debate is whether the company's stellar 117% YoY revenue growth and 67% net margins can justify and sustain its premium valuation (P/E ~23x) in the face of rising interest rates and a weakening technical picture for the REIT sector. The resolution of this growth-versus-valuation tension will determine the stock's direction.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 117.1% YoY to $135.05M, accelerating from prior quarters, driven by strategic acquisitions. This demonstrates powerful top-line expansion and successful execution of the growth strategy.
- Exceptional Profitability & Margins: Trailing net margin is an extraordinary 67.26%, with a Q4 operating margin of 64.10%, reflecting the highly efficient triple-net lease model. The model passes property-level costs to tenants, creating a predictable, high-margin income stream.
- Strong Financial Health & Cash Flow: The balance sheet is conservative with a debt-to-equity ratio of 0.22 and a current ratio of 1.54. Robust TTM free cash flow of $379.04M comfortably supports the 3.5% dividend yield, evidenced by an 80.9% payout ratio based on earnings.
- Long-Term Technical Uptrend: Despite recent weakness, the stock is up 27.03% over the past year, outperforming the S&P 500 (+22.86%). This indicates a strong underlying uptrend, with the current pullback potentially offering a better entry point.
Bearish
- Severe Recent Momentum Breakdown: The stock is down -13.17% over the past month and -7.94% over three months, underperforming the S&P 500 by -19.94% over three months. This sharp reversal signals significant near-term selling pressure and loss of bullish conviction.
- Premium Valuation Metrics: The trailing P/E of 22.97x and P/S of 15.45x are elevated for a REIT, pricing in high growth expectations. The forward P/E of 21.15x suggests only modest earnings growth is anticipated, which may not justify the current premium if growth slows.
- Limited Analyst Coverage: Only one analyst provides estimates, indicating limited institutional research and potentially less efficient price discovery. This can lead to higher volatility and greater susceptibility to macro or sector-specific sentiment shifts.
- High Dependence on Acquisition Growth: The explosive 117% YoY revenue growth is driven by acquisitions, not organic same-store growth. This strategy requires continuous capital deployment and successful integration, posing execution and funding risks if market conditions tighten.
CTRE Technical Analysis
The stock is in a clear uptrend over the past year, with a 1-year price change of +27.03%, significantly outperforming the S&P 500's +22.86% gain. However, it is currently trading at $36.85, which is only about 14.5% above its 52-week low of $27.81 and 14.5% below its 52-week high of $43.08, positioning it in the lower-middle portion of its annual range. This suggests the strong longer-term uptrend has recently experienced a significant pullback, presenting a potential entry point but also indicating a loss of near-term momentum. Recent momentum has been sharply negative, with the stock down -13.17% over the past month and -7.94% over the past three months, diverging starkly from its positive 1-year trend and significantly underperforming the S&P 500's 3-month gain of +12.0%. This sharp reversal, highlighted by a relative strength of -19.94 over three months, signals a significant loss of bullish conviction, likely driven by sector-wide pressures on REITs or a reaction to company-specific news. Key technical support is at the 52-week low of $27.81, while resistance is at the recent high of $43.08. A sustained break below the recent June lows near $36.75 could signal a deeper correction towards the $27.81 level, while a recovery above $41 would be needed to re-establish the uptrend. The stock's beta of 0.786 indicates it is historically about 21% less volatile than the broader market, which is typical for a REIT but does not preclude sharp sector-driven moves as seen recently.
Beta
0.79
0.79x market volatility
Max Drawdown
-13.4%
Largest decline past year
52-Week Range
$28-$43
Price range past year
Annual Return
+31.8%
Cumulative gain past year
| Period | CTRE Return | S&P 500 |
|---|---|---|
| 1m | -10.0% | +1.5% |
| 3m | -7.2% | +13.4% |
| 6m | +2.1% | +10.9% |
| 1y | +31.8% | +24.5% |
| ytd | +2.0% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTRE Fundamental Analysis
Revenue growth has been robust and accelerating, with Q4 2025 revenue of $135.05 million representing a 117.1% year-over-year increase, building on a strong sequential trend from $104.27 million in Q3 and $86.03 million in Q2. This explosive growth is primarily driven by strategic acquisitions and portfolio expansion within its single reportable segment of healthcare real estate. The company is highly profitable, with Q4 2025 net income of $111.29 million and a trailing net margin of 67.26%. Gross margin for the quarter was 58.93%, and the operating margin was 64.10%, indicating efficient operations and the benefit of its triple-net lease structure, which passes most property-level costs to tenants. The balance sheet and cash flow position are solid, with a low debt-to-equity ratio of 0.22 and a current ratio of 1.54, reflecting a conservative capital structure and good short-term liquidity. Trailing twelve-month free cash flow is a strong $379.04 million, providing ample coverage for its dividend, which has a payout ratio of 80.9% based on earnings, and internal funding for growth initiatives. The Return on Equity (ROE) of 7.94% and Return on Assets (ROA) of 4.76% demonstrate adequate, if not spectacular, returns on capital employed.
Quarterly Revenue
$135052000.0B
2025-12
Revenue YoY Growth
+1.17%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$379037000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTRE Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 22.97x, while the forward P/E is 21.15x, indicating the market expects modest earnings growth. The slight discount of the forward multiple suggests expectations for a slight acceleration in earnings or a moderation from the recent high growth rates. Compared to the broader Real Estate sector (implied average P/E not provided in data), a direct industry comparison is unavailable; however, a P/E in the low 20s for a growing healthcare REIT with a 67% net margin could be considered reasonable if growth persists. The stock's current Price-to-Book (P/B) ratio of 1.82 is near the middle of its recent historical range, which has fluctuated between approximately 1.69 and 2.42 over the past few years, suggesting it is not at an extreme valuation level on this metric. Historically, the stock's trailing P/E has ranged from deeply negative figures during periods of loss to highs above 80x during low-earnings periods; the current 22.97x is moderate by its own history, indicating the market is valuing its current, more stable profitability profile rather than speculative future growth.
PE
23.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -1017x~617x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation, not solvency. The company's low debt-to-equity ratio of 0.22 and strong free cash flow of $379M TTM mitigate traditional balance sheet concerns. However, the core risk is the sustainability of its acquisition-driven growth model, which fueled a 117% YoY revenue surge. A slowdown in the pace or return profile of acquisitions could cause the premium P/E of 22.97x to compress sharply. The 80.9% earnings-based dividend payout ratio, while covered, leaves limited cushion for a significant earnings miss without pressure on the dividend.
Market & Competitive Risks: The stock faces significant market risk from interest rate sensitivity, a hallmark of the REIT sector. Despite a low beta of 0.786, the recent -13% one-month drop amid broader market stability suggests it is being punished by rising rate expectations. Its premium P/E and P/S (15.45x) multiples are vulnerable to compression if sector-wide multiple contraction occurs. Competitive risks are moderate, as its triple-net lease model in healthcare is defensible, but tenant concentration or operator distress in its skilled nursing and senior housing portfolio could disrupt cash flows.
Worst-Case Scenario: A perfect storm of persistently high interest rates, a failed acquisition integration, and a sector-wide REIT sell-off could trigger a re-rating to its historical valuation lows. This could see the stock retest its 52-week low of $27.81, representing a potential downside of -24.5% from the current price of $36.85. The chain of events would likely involve a guidance cut on acquisition pace, leading to analyst downgrades (though coverage is sparse), and a breach of key technical support near $36.75, accelerating the sell-off towards the $27.81 level.
FAQ
The key risks are: 1) Interest Rate Risk (High Severity): As a REIT, CTRE is highly sensitive to rising rates, which increase its cost of capital for acquisitions and make its yield less attractive relative to bonds. The recent -13% monthly drop demonstrates this sensitivity. 2) Acquisition Dependency Risk (Medium-High): Its 117% revenue growth is not organic; a slowdown in the pace or profitability of acquisitions would immediately hurt growth and likely the multiple. 3) Valuation Risk (Medium): The premium P/E of ~23x is vulnerable to compression if growth moderates or sector sentiment sours. 4) Limited Liquidity & Coverage Risk (Medium): With only one analyst providing estimates, the stock may experience sharper moves on news and have less institutional support.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $36 and $40 as strong fundamentals offset rate headwinds. The Bull Case (25% probability) projects a return to the $42-$43.08 range on successful acquisitions and a dovish Fed pivot. The Bear Case (20% probability) warns of a drop to the $27.81-$32 range if high rates persist and growth stalls. The most likely outcome is the Base Case, which assumes revenue growth moderates but remains healthy (15-25%) and the current technical support near $36.75 holds. The average analyst EPS estimate is $1.69, but no consensus price target is available.
CTRE appears fairly valued to slightly overvalued based on current metrics. Its trailing P/E of 22.97x and forward P/E of 21.15x are at a premium, demanding continued high growth. The P/S ratio of 15.45x is also elevated. While these multiples are justified by its exceptional 67% net margin and recent explosive growth, they leave little room for error. Compared to its own 52-week trading range, the stock is in the lower-middle portion, suggesting some recent multiple compression. The valuation implies the market expects the company to sustain its acquisition-fueled growth trajectory; any stumble would likely trigger significant multiple contraction.
CTRE is a HOLD, not a compelling buy at the current price of $36.85. The company's fundamentals are excellent, with 117% YoY revenue growth and a 67% net margin, but the stock's premium valuation (P/E 22.97x) and recent severe technical breakdown (-13% in one month) suggest these strengths are already priced in. For a new buyer, the risk/reward is balanced at best. It could become a good buy for long-term investors if it pulls back further, offering a higher margin of safety, or if the technical picture stabilizes above key support. Income investors may find the 3.5% yield attractive, but must accept potential near-term price volatility.
CTRE is primarily suitable for a long-term investment horizon of 3-5 years. Its business model as a growing healthcare REIT is built for compounding through acquisitions and reliable dividends. The low beta of 0.786 indicates lower long-term volatility relative to the market, aligning with a buy-and-hold strategy. However, the recent severe short-term underperformance (-7.94% over 3 months) and sensitivity to interest rates make it a poor candidate for short-term trading. The 3.5% dividend yield supports a total-return approach for income-oriented portfolios. A minimum holding period of 2-3 years is suggested to ride out sector volatility and allow the company's growth strategy to play out.